Antibody-mediated neutralization of flaviviruses: A reductionist view

Virology

Volumn 411, Issue 2, 2011, Pages 306-315

  Dowd, Kimberly A ^a   Pierson, Theodore C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antibody dependent enhancement of infection; Antibody mediated neutralization; Complement; Dengue virus; Flavivirus; West Nile virus

Indexed keywords

CD209 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5; COMPLEMENT MEMBRANE ATTACK COMPLEX; EPITOPE; FC RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E16; MONOCLONAL ANTIBODY E53; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIGEN BINDING; COMPLEMENT SYSTEM; CONFORMATIONAL TRANSITION; DENGUE VIRUS; FLAVIVIRUS; FLAVIVIRUS INFECTION; HUMAN; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; REVIEW; STOICHIOMETRY; VIRION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS PATHOGENESIS; WEST NILE FLAVIVIRUS;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; FLAVIVIRUS; HUMANS;

DENGUE VIRUS; FLAVIVIRUS; RNA VIRUSES; WEST NILE VIRUS;

EID: 79952071242     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.12.020     Document Type: Review

References (120)

1. Aaskov J.G., Williams L., Fletcher J., Hay R. Failure of a dengue 1 sub-unit vaccine to protect mice against a lethal dengue virus infection. Am. J. Trop. Med. Hyg. 1988, 39(5):511-518.
2. Balsitis S.J., Williams K.L., Lachica R., Flores D., Kyle J.L., Mehlhop E., Johnson S., Diamond M.S., Beatty P.R., Harris E. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 2010, 6(2):e1000790.
3. Barrett A.D., Teuwen D.E. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?. Curr. Opin. Immunol. 2009, 21(3):308-313.
4. Beasley D.W., Barrett A.D. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 2002, 76(24):13097-13100.
5. Beltramello M., Williams K.L., Simmons C.P., Macagno A., Simonelli L., Quyen N.T., Sukupolvi-Petty S., Navarro-Sanchez E., Young P.R., de Silva A.M., Rey F.A., Varani L., Whitehead S.S., Diamond M.S., Harris E., Lanzavecchia A., Sallusto F. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010, 8(3):271-283.
6. Benhnia M.R., McCausland M.M., Laudenslager J., Granger S.W., Rickert S., Koriazova L., Tahara T., Kubo R.T., Kato S., Crotty S. Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J. Virol. 2009, 83(23):12355-12367.
7. Boehr D.D., Wright P.E. Biochemistry. How do proteins interact?. Science 2008, 320(5882):1429-1430.
8. Boonnak K., Slike B.M., Burgess T.H., Mason R.M., Wu S.J., Sun P., Porter K., Rudiman I.F., Yuwono D., Puthavathana P., Marovich M.A. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J. Virol. 2008, 82(8):3939-3951.
9. Booy F.P., Roden R.B., Greenstone H.L., Schiller J.T., Trus B.L. Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution. J. Mol. Biol. 1998, 281(1):95-106.
10. Bothner B., Dong X.F., Bibbs L., Johnson J.E., Siuzdak G. Evidence of viral capsid dynamics using limited proteolysis and mass spectrometry. J. Biol. Chem. 1998, 273(2):673-676.
11. Brien J.D., Austin S.K., Sukupolvi-Petty S., O'Brien K.M., Johnson S., Fremont D.H., Diamond M.S. Genotype specific neutralization and protection by antibodies against dengue virus type 3. J. Virol. 2010, 84(20):10603-10643.
12. Burnet F.M., Keogh E.V., Lush D. The immunological reactions of the filterable viruses. Aust. J. Exp. Biol. Med. Sci. 1937, 15:227-368.
13. Burton D.R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2002, 2(9):706-713.
14. Burton D.R., Saphire E.O., Parren P.W. A model for neutralization of viruses based on antibody coating of the virion surface. Curr. Top. Microbiol. Immunol. 2001, 260:109-143.
15. Chareonsirisuthigul T., Kalayanarooj S., Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J. Gen. Virol. 2007, 88(Pt 2):365-375.
16. Cherrier M.V., Kaufmann B., Nybakken G.E., Lok S.M., Warren J.T., Chen B.R., Nelson C.A., Kostyuchenko V.A., Holdaway H.A., Chipman P.R., Kuhn R.J., Diamond M.S., Rossmann M.G., Fremont D.H. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J. 2009, 28(20):3269-3276.
17. Crill W.D., Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 2001, 75(16):7769-7773.
18. Crill W.D., Trainor N.B., Chang G.J. A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles. J. Gen. Virol. 2007, 88(Pt 4):1169-1174.
19. Crill W.D., Hughes H.R., Delorey M.J., Chang G.J. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS ONE 2009, 4(4):e4991.
20. Davis C.W., Nguyen H.Y., Hanna S.L., Sanchez M.D., Doms R.W., Pierson T.C. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J. Virol. 2006, 80(3):1290-1301.
21. Dejnirattisai W., Jumnainsong A., Onsirisakul N., Fitton P., Vasanawathana S., Limpitikul W., Puttikhunt C., Edwards C., Duangchinda T., Supasa S., Chawansuntati K., Malasit P., Mongkolsapaya J., Screaton G. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328(5979):745-748.
22. Della-Porta A.J., Westaway E.G. A multi-hit model for the neutralization of animal viruses. J. Gen. Virol. 1978, 38(1):1-19.
23. Dulbecco R., Vogt M., Strickland A.G. A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus. Virology 1956, 2(2):162-205.
24. Elshuber S., Allison S.L., Heinz F.X., Mandl C.W. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J. Gen. Virol. 2003, 84(Pt 1):183-191.
25. Feng J.Q., Mozdzanowska K., Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J. Virol. 2002, 76(3):1369-1378.
26. Flamand A., Raux H., Gaudin Y., Ruigrok R.W. Mechanisms of rabies virus neutralization. Virology 1993, 194(1):302-313.
27. Gollins S.W., Porterfield J.S. A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 1986, 321(6067):244-246.
28. Goncalvez A.P., Engle R.E., St Claire M., Purcell R.H., Lai C.J. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl Acad. Sci. USA 2007, 104(22):9422-9427.
29. Green S., Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr. Opin. Infect. Dis. 2006, 19(5):429-436.
30. Gromowski G.D., Barrett A.D. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 2007, 366(2):349-360.
31. Gromowski G.D., Barrett N.D., Barrett A.D. Characterization of dengue complex-specific neutralizing epitopes on the envelope protein domain III of dengue 2 virus. J. Virol. 2008, 82(17):8828-8837.
32. Gromowski G.D., Roehrig J.T., Diamond M.S., Lee J.C., Pitcher T.J., Barrett A.D. Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. Virology 2010, 407(2):237-246.
33. Guirakhoo F., Heinz F.X., Mandl C.W., Holzmann H., Kunz C. Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. J. Gen. Virol. 1991, 72(Pt 6):1323-1329.
34. Guirakhoo F., Bolin R.A., Roehrig J.T. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology 1992, 191(2):921-931.
35. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28(3):632-649.
36. Halstead S.B. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 1979, 140(4):527-533.
37. Halstead S.B. Dengue. Curr. Opin. Infect. Dis. 2002, 15(5):471-476.
38. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 2003, 60:421-467.
39. Halstead S.B., O'Rourke E.J. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977, 265(5596):739-741.
40. Halstead S.B., Thomas S.J. Japanese encephalitis: new options for active immunization. Clin. Infect. Dis. 2010, 50(8):1155-1164.
41. Harrison S.C. Viral membrane fusion. Nat. Struct. Mol. Biol. 2008, 15(7):690-698.
42. Hawkes R.A. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust. J. Exp. Biol. Med. Sci. 1964, 42:465-482.
43. He R.T., Innis B.L., Nisalak A., Usawattanakul W., Wang S., Kalayanarooj S., Anderson R. Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J. Med. Virol. 1995, 45(4):451-461.
44. Heinz F.X., Stiasny K., Puschner-Auer G., Holzmann H., Allison S.L., Mandl C.W., Kunz C. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology 1994, 198(1):109-117.
45. Heinz F.X., Holzmann H., Essl A., Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 2007, 25(43):7559-7567.
46. Huang K.J., Yang Y.C., Lin Y.S., Huang J.H., Liu H.S., Yeh T.M., Chen S.H., Liu C.C., Lei H.Y. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J. Immunol. 2006, 176(5):2825-2832.
47. Icenogle J., Shiwen H., Duke G., Gilbert S., Rueckert R., Anderegg J. Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry. Virology 1983, 127(2):412-425.
48. Johnson J.E. Virus particle dynamics. Adv. Protein Chem. 2003, 64:197-218.
49. Junjhon J., Edwards T.J., Utaipat U., Bowman V.D., Holdaway H.A., Zhang W., Keelapang P., Puttikhunt C., Perera R., Chipman P.R., Kasinrerk W., Malasit P., Kuhn R.J., Sittisombut N. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J. Virol. 2010, 84(16):8353-8358.
50. Kaufman B.M., Summers P.L., Dubois D.R., Cohen W.H., Gentry M.K., Timchak R.L., Burke D.S., Eckels K.H. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 1989, 41(5):576-580.
51. Kaufmann B., Nybakken G.E., Chipman P.R., Zhang W., Diamond M.S., Fremont D.H., Kuhn R.J., Rossmann M.G. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc. Natl Acad. Sci. USA 2006, 103(33):12400-12404.
52. Kaufmann B., Chipman P.R., Holdaway H.A., Johnson S., Fremont D.H., Kuhn R.J., Diamond M.S., Rossmann M.G. Capturing a flavivirus pre-fusion intermediate. PLoS Pathog. 2009, 5(11):e1000672.
53. Kaufmann B., Vogt M.R., Goudsmit J., Holdaway H.A., Aksyuk A.A., Chipman P.R., Kuhn R.J., Diamond M.S., Rossmann M.G. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl Acad. Sci. USA 2010, 107(44):18950-18955.
54. Kiermayr S., Stiasny K., Heinz F.X. Impact of quaternary organization on the antigenic structure of the tick-borne encephalitis virus envelope glycoprotein E. J. Virol. 2009, 83(17):8482-8491.
55. Kishore U., Reid K.B. C1q: structure, function, and receptors. Immunopharmacology 2000, 49(1-2):159-170.
56. Klasse P.J., Burton D.R. Antibodies to West Nile virus: a double-edged sword. Cell Host Microbe 2007, 1(2):87-89.
57. Klasse P.J., Sattentau Q.J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 2002, 83(Pt 9):2091-2108.
58. Klein J.S., Gnanapragasam P.N., Galimidi R.P., Foglesong C.P., West A.P., Bjorkman P.J. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc. Natl Acad. Sci. USA 2009, 106(18):7385-7390.
59. Kliks S.C., Nimmanitya S., Nisalak A., Burke D.S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 1988, 38(2):411-419.
60. Kliks S.C., Nisalak A., Brandt W.E., Wahl L., Burke D.S. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 1989, 40(4):444-451.
61. Kuhn R.J., Zhang W., Rossmann M.G., Pletnev S.V., Corver J., Lenches E., Jones C.T., Mukhopadhyay S., Chipman P.R., Strauss E.G., Baker T.S., Strauss J.H. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002, 108(5):717-725.
62. Lai C.Y., Tsai W.Y., Lin S.R., Kao C.L., Hu H.P., King C.C., Wu H.C., Chang G.J., Wang W.K. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J. Virol. 2008, 82(13):6631-6643.
63. Lambris J.D., Ricklin D., Geisbrecht B.V. Complement evasion by human pathogens. Nat. Rev. Microbiol. 2008, 6(2):132-142.
64. Leatherbarrow R.J., Dwek R.A. Binding of complement subcomponent C1q to mouse IgG1, IgG2a and IgG2b: a novel C1q binding assay. Mol. Immunol. 1984, 21(4):321-327.
65. Lewis J.K., Bothner B., Smith T.J., Siuzdak G. Antiviral agent blocks breathing of the common cold virus. Proc. Natl Acad. Sci. USA 1998, 95(12):6774-6778.
66. Li Q., Yafal A.G., Lee Y.M., Hogle J., Chow M. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature. J. Virol. 1994, 68(6):3965-3970.
67. Li L., Lok S.M., Yu I.M., Zhang Y., Kuhn R.J., Chen J., Rossmann M.G. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 2008, 319(5871):1830-1834.
68. Lindenbach B.D., Thiel H.J., Rice C.M. Flaviviridae: The Viruses and Their Replication. Fields Virology 2007, Vol. 1:1101-1152. Lippincott-Williams & Wilkins, Philadelphia, 2 vols. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
69. Lok S.M., Kostyuchenko V., Nybakken G.E., Holdaway H.A., Battisti A.J., Sukupolvi-Petty S., Sedlak D., Fremont D.H., Chipman P.R., Roehrig J.T., Diamond M.S., Kuhn R.J., Rossmann M.G. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 2008, 15(3):312-317.
70. Mandel B. Neutralization of poliovirus: a hypothesis to explain the mechanism and the one-hit character of the neutralization reaction. Virology 1976, 69(2):500-510.
71. Mandl C.W., Guirakhoo F., Holzmann H., Heinz F.X., Kunz C. Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model. J. Virol. 1989, 63(2):564-571.
72. Mehlhop E., Ansarah-Sobrinho C., Johnson S., Engle M., Fremont D.H., Pierson T.C., Diamond M.S. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2007, 2(6):417-426.
73. Mehlhop E., Nelson S., Jost C.A., Gorlatov S., Johnson S., Fremont D.H., Diamond M.S., Pierson T.C. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 2009, 6(4):381-391.
74. Moi M.L., Lim C.K., Takasaki T., Kurane I. Involvement of the Fc gamma receptor IIA cytoplasmic domain in antibody-dependent enhancement of dengue virus infection. J. Gen. Virol. 2010, 91(Pt 1):103-111.
75. Morens D.M., Halstead S.B., Marchette N.J. Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microb. Pathog. 1987, 3(4):231-237.
76. Morrey J.D., Siddharthan V., Olsen A.L., Roper G.Y., Wang H., Baldwin T.J., Koenig S., Johnson S., Nordstrom J.L., Diamond M.S. Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J. Infect. Dis. 2006, 194(9):1300-1308.
77. Mouquet H., Scheid J.F., Zoller M.J., Krogsgaard M., Ott R.G., Shukair S., Artyomov M.N., Pietzsch J., Connors M., Pereyra F., Walker B.D., Ho D.D., Wilson P.C., Seaman M.S., Eisen H.N., Chakraborty A.K., Hope T.J., Ravetch J.V., Wardemann H., Nussenzweig M.C. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010, 467(7315):591-595.
78. Mukhopadhyay S., Kim B.S., Chipman P.R., Rossmann M.G., Kuhn R.J. Structure of West Nile virus. Science 2003, 302(5643):248.
79. Mukhopadhyay S., Kuhn R.J., Rossmann M.G. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 2005, 3(1):13-22.
80. Nelson S., Jost C.A., Xu Q., Ess J., Martin J.E., Oliphant T., Whitehead S.S., Durbin A.P., Graham B.S., Diamond M.S., Pierson T.C. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 2008, 4(5):e1000060.
81. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8(1):34-47.
82. Nybakken G.E., Oliphant T., Johnson S., Burke S., Diamond M.S., Fremont D.H. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 2005, 437(7059):764-769.
83. Oliphant T., Engle M., Nybakken G.E., Doane C., Johnson S., Huang L., Gorlatov S., Mehlhop E., Marri A., Chung K.M., Ebel G.D., Kramer L.D., Fremont D.H., Diamond M.S. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 2005, 11(6):522-530.
84. Oliphant T., Nybakken G.E., Engle M., Xu Q., Nelson C.A., Sukupolvi-Petty S., Marri A., Lachmi B.E., Olshevsky U., Fremont D.H., Pierson T.C., Diamond M.S. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J. Virol. 2006, 80(24):12149-12159.
85. Oliphant T., Nybakken G.E., Austin S.K., Xu Q., Bramson J., Loeb M., Throsby M., Fremont D.H., Pierson T.C., Diamond M.S. Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 2007, 81(21):11828-11839.
86. Parren P.W., Burton D.R. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 2001, 77:195-262.
87. Peiris J.S., Gordon S., Unkeless J.C., Porterfield J.S. Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages. Nature 1981, 289(5794):189-191.
88. Pierson T.C., Xu Q., Nelson S., Oliphant T., Nybakken G.E., Fremont D.H., Diamond M.S. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 2007, 1(2):135-145.
89. Pierson T.C., Fremont D.H., Kuhn R.J., Diamond M.S. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 2008, 4(3):229-238.
90. Porterfield J.S. Antibody-dependent enhancement of viral infectivity. Adv. Virus Res. 1986, 31:335-355.
91. Roden R.B., Weissinger E.M., Henderson D.W., Booy F., Kirnbauer R., Mushinski J.F., Lowy D.R., Schiller J.T. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J. Virol. 1994, 68(11):7570-7574.
92. Rodenhuis-Zybert I.A., van der Schaar H.M., da Silva Voorham J.M., van der Ende-Metselaar H., Lei H.Y., Wilschut J., Smit J.M. Immature dengue virus: a veiled pathogen?. PLoS Pathog. 2010, 6(1):e1000718.
93. Rodrigo W.W., Jin X., Blackley S.D., Rose R.C., Schlesinger J.J. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J. Virol. 2006, 80(20):10128-10138.
94. Roehrig J.T. Antigenic structure of flavivirus proteins. Adv. Virus Res. 2003, 59:141-175.
95. Roehrig J.T., Bolin R.A., Kelly R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998, 246(2):317-328.
96. Roehrig J.T., Staudinger L.A., Hunt A.R., Mathews J.H., Blair C.D. Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann. NY Acad. Sci. 2001, 951:286-297.
97. Sanchez M.D., Pierson T.C., Degrace M.M., Mattei L.M., Hanna S.L., Del Piero F., Doms R.W. The neutralizing antibody response against West Nile virus in naturally infected horses. Virology 2007, 359(2):336-348.
98. Sawyer L.A. Antibodies for the prevention and treatment of viral diseases. Antivir. Res. 2000, 47(2):57-77.
99. Schumaker V.N., Calcott M.A., Spiegelberg H.L., Muller-Eberhard H.J. Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry 1976, 15(23):5175-5181.
100. Shepherd C.M., Borelli I.A., Lander G., Natarajan P., Siddavanahalli V., Bajaj C., Johnson J.E., Brooks C.L., Reddy V.S. VIPERdb: a relational database for structural virology. Nucleic Acids Res. 2006, 34:D386-D389. Database issue.
101. Shrestha B., Brien J.D., Sukupolvi-Petty S., Austin S.K., Edeling M.A., Kim T., O'Brien K.M., Nelson C.A., Johnson S., Fremont D.H., Diamond M.S. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 2010, 6(4):e1000823.
102. Stiasny K., Kiermayr S., Holzmann H., Heinz F.X. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 2006, 80(19):9557-9568.
103. Stiasny K., Brandler S., Kossl C., Heinz F.X. Probing the flavivirus membrane fusion mechanism by using monoclonal antibodies. J. Virol. 2007, 81(20):11526-11531.
104. Sukupolvi-Petty S., Austin S.K., Purtha W.E., Oliphant T., Nybakken G.E., Schlesinger J.J., Roehrig J.T., Gromowski G.D., Barrett A.D., Fremont D.H., Diamond M.S. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 2007, 81(23):12816-12826.
105. Sukupolvi-Petty S., Austin S.K., Engle M., Brien J.D., Dowd K.A., Williams K.L., Johnson S., Rico-Hesse R., Harris E., Pierson T.C., Fremont D.H., Diamond M.S. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J. Virol. 2010, 84(18):9227-9239.
106. Thompson B.S., Moesker B., Smit J.M., Wilschut J., Diamond M.S., Fremont D.H. A therapeutic antibody against West Nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog. 2009, 5(5):e1000453.
107. Throsby M., Geuijen C., Goudsmit J., Bakker A.Q., Korimbocus J., Kramer R.A., Clijsters-van der Horst M., de Jong M., Jongeneelen M., Thijsse S., Smit R., Visser T.J., Bijl N., Marissen W.E., Loeb M., Kelvin D.J., Preiser W., ter Meulen J., de Kruif J. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J. Virol. 2006, 80(14):6982-6992.
108. Ubol S., Phuklia W., Kalayanarooj S., Modhiran N. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J. Infect. Dis. 2010, 201(6):923-935.
109. Vazquez S., Guzman M.G., Guillen G., Chinea G., Perez A.B., Pupo M., Rodriguez R., Reyes O., Garay H.E., Delgado I., Garcia G., Alvarez M. Immune response to synthetic peptides of dengue prM protein. Vaccine 2002, 20(13-14):1823-1830.
110. Vogt M.R., Moesker B., Goudsmit J., Jongeneelen M., Austin S.K., Oliphant T., Nelson S., Pierson T.C., Wilschut J., Throsby M., Diamond M.S. Human monoclonal antibodies induced by natural infection against West Nile virus neutralize at a post-attachment step. J. Virol. 2009, 83(13):6494-6507.
111. Wahala W.M., Kraus A.A., Haymore L.B., Accavitti-Loper M.A., de Silva A.M. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009, 392(1):103-113.
112. Wahala W.M., Donaldson E.F., de Alwis R., Accavitti-Loper M.A., Baric R.S., de Silva A.M. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog. 2010, 6(3):e1000821.
113. Whitehead S.S., Blaney J.E., Durbin A.P., Murphy B.R. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 2007, 5(7):518-528.
114. Whiteman M.C., Li L., Wicker J.A., Kinney R.M., Huang C., Beasley D.W., Chung K.M., Diamond M.S., Solomon T., Barrett A.D. Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. Vaccine 2010, 28(4):1075-1083.
115. Witz J., Brown F. Structural dynamics, an intrinsic property of viral capsids. Arch. Virol. 2001, 146(12):2263-2274.
116. Yamanaka A., Kosugi S., Konishi E. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J. Virol. 2008, 82(2):927-937.
117. Yu I.M., Zhang W., Holdaway H.A., Li L., Kostyuchenko V.A., Chipman P.R., Kuhn R.J., Rossmann M.G., Chen J. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 2008, 319(5871):1834-1837.
118. Zellweger R.M., Prestwood T.R., Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 2010, 7(2):128-139.
119. Zhang Y., Corver J., Chipman P.R., Zhang W., Pletnev S.V., Sedlak D., Baker T.S., Strauss J.H., Kuhn R.J., Rossmann M.G. Structures of immature flavivirus particles. EMBO J. 2003, 22(11):2604-2613.
120. Zhang Y., Kaufmann B., Chipman P.R., Kuhn R.J., Rossmann M.G. Structure of immature West Nile virus. J. Virol. 2007, 81(11):6141-6145.